Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  •
  • MyStocks
MEMBER'S LOGIN

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Will Indian pharma buckle under regulations?
Tue, 21 Apr Pre-Open

Indian pharma companies have been facing the heat from a stringent US Food and Drug Administration (USFDA). As a majority of domestic generic companies derive a lion's share of revenues from the US market, the largest number of FDA-approved plants outside the US belongs to them.

In recent times, several domestic pharma companies have been pulled up for data integrity issues that include deficiency in manufacturing practices and drug tests. This has led to import alerts against companies such Sun Pharma, Wockhardt, Cadila Pharma, Orchid Pharma and Ipca Labs. In extreme cases, companies such as Ranbaxy were penalized with import bans imposed on some of its plants.

Apart from this, higher vigilance by USFDA has led to increase in waiting period for new drug approvals from 30 months to 42 months. This has pulled down the number of approvals from 100 in FY14 to 57 in FY15. Resultantly, domestic drug companies are expected to witness pressure on earnings in the short run.

However, the long term demand potential for generic drug companies remains bright. Indian drug companies have been strengthening quality and control processes to comply with USFDA's strict rules. As a result, the number of import alerts has come down from 21 in 2013 to 8 in 2014 (Source: India Ratings and Research).

According to The World Generic Medicines Congress Europe 2015, the patent on drugs valued at US$ 170 bn are set to expire in 2015 spurring demand for generics with the US market alone accounting for a huge share of 86-87%. It remains to be seen how well Indian drug companies will gear up to tap this huge off-patent drugs opportunity.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

RSS RSS

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Will Indian pharma buckle under regulations?". Click here!

  

Views on News

Mirae Asset Tax Saver Fund: Seizing Superior Growth Opportunities (Outside View)

Apr 9, 2021

PersonalFN's analysis on the features and performance of Mirae Asset Tax Saver Fund.

Time to Change Our Trading Blueprint? (Fast Profits Daily)

Apr 9, 2021

The Indian government recently announced cut backs on crude oil imports from Saudi Arabia. Does this change our crude oil trading blueprint. Find out...

An India Revival Stock I'm Bullish On... (Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Key Reasons Why Mutual Funds Turned Net Buyers in March 2021 (Outside View)

Apr 8, 2021

Domestic mutual funds have turned net buyers worth Rs 2,476 crore in the Indian equity markets in March 2021 for the first time in the last 10 months.

The Indians Are Coming (Fast Profits Daily)

Apr 8, 2021

In this video, I'll tell you why the Indian consumer has started to take the price of gold and silver higher.

More Views on News

Most Popular

A Critical Update on the Market (Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy (Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers (Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

India's Revival: A Once-in-a-generation Wealth Making Opportunity
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

S&P BSE SENSEX


Apr 9, 2021 (Close)

FEATURED VIDEOS

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

Kalyan Jewellers IPO: An Honest View

More Featured Videos

MARKET STATS


ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
  • Follow on YouTube
  • Follow on LinkedIn Follow @Equitymaster Follow on RSS Follow on Telegram

APP
  • Get Equitymaster Android App on Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.